You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 15, 2025

CLINICAL TRIALS PROFILE FOR PROPECIA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Propecia

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00381108 ↗ Study of the Effects of Pomegranate Tablets on Enlarged Prostates Unknown status Jarrow Pharmaceuticals Phase 1 2005-09-01 To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic Hyperplasia.
NCT00381108 ↗ Study of the Effects of Pomegranate Tablets on Enlarged Prostates Unknown status Pomegranate Health Phase 1 2005-09-01 To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic Hyperplasia.
NCT00381108 ↗ Study of the Effects of Pomegranate Tablets on Enlarged Prostates Unknown status University of California, Irvine Phase 1 2005-09-01 To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic Hyperplasia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Propecia

Condition Name

Condition Name for Propecia
Intervention Trials
Prostate Cancer 2
Healthy 2
Healthy Males 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Propecia
Intervention Trials
Alopecia 3
Prostatic Neoplasms 2
Alopecia Areata 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Propecia

Trials by Country

Trials by Country for Propecia
Location Trials
United States 6
Canada 2
Belgium 1
Russian Federation 1
Hungary 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Propecia
Location Trials
Illinois 1
Missouri 1
Kansas 1
Washington 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Propecia

Clinical Trial Phase

Clinical Trial Phase for Propecia
Clinical Trial Phase Trials
Phase 3 1
Phase 2 1
Phase 1/Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Propecia
Clinical Trial Phase Trials
Completed 6
Not yet recruiting 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Propecia

Sponsor Name

Sponsor Name for Propecia
Sponsor Trials
Dr. Reddy's Laboratories Limited 2
University of California, Irvine 1
National Eye Institute (NEI) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Propecia
Sponsor Trials
Industry 6
Other 5
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Propecia (Finasteride): Clinical Trials, Market Analysis, and Projections

Introduction to Propecia

Propecia, known generically as finasteride, is a medication primarily used to treat male pattern hair loss and benign prostatic hyperplasia (BPH). Here, we will delve into the clinical trials, market analysis, and future projections for this widely used drug.

Clinical Trials Overview

Efficacy in Hair Loss Treatment

Clinical trials for Propecia have demonstrated its efficacy in treating male pattern hair loss. In a study involving over 1800 men aged 18 to 41 with mild to moderate hair loss, Propecia showed significant results. After 12 months of treatment, 58% of men in the placebo group experienced further hair loss, compared to only 14% of men treated with Propecia. By the fifth year of the study, investigators rated 77% of men treated with Propecia as having increased hair growth, versus 15% in the placebo group[1].

Long-Term Effects and Discontinuation

The studies also evaluated the long-term effects and the impact of discontinuing the treatment. Men who switched from Propecia to placebo after the initial 12 months saw a reversal of the hair growth benefits by the 24th month. However, those who continued or resumed Propecia treatment maintained the benefits of increased hair growth[1].

Adverse Effects

Clinical trials have also highlighted the potential adverse effects of Propecia. In three controlled clinical trials, 1.4% of patients taking Propecia were discontinued due to drug-related adverse experiences, such as decreased libido, erectile dysfunction, and ejaculation disorders. However, these side effects were generally reversible upon discontinuation of the drug, and their incidence decreased significantly by the fifth year of treatment[4].

Market Analysis

Current Market Size

As of 2025, the global finasteride market size is valued at approximately USD 115.04 million. This market is driven by the increasing prevalence of male pattern baldness and BPH, along with rising awareness about hair loss treatments and aesthetic procedures[5].

Growth Drivers

Several factors are driving the growth of the finasteride market:

  • Increasing Prevalence of Hair Loss and BPH: The rising incidence of male pattern baldness and BPH is a significant driver.
  • Rising Awareness and Adoption: Growing awareness about hair loss treatments and the increasing adoption of aesthetic procedures are contributing to market growth.
  • Economic Factors: Increasing disposable income and the growing trend of self-grooming among men are also driving the market[2][5].

Market Projections

The finasteride market is projected to grow at a CAGR of around 2.7% from 2025 to 2037, reaching an estimated value of USD 159.01 million by 2037. This growth is expected to be sustained by the increasing demand for hair loss treatments and the expanding geriatric population, which is more prone to BPH and other related conditions[5].

Market Trends and Insights

Global Demand

The global demand for finasteride is increasing due to its dual use in treating both hair loss and BPH. This dual functionality makes it a versatile and sought-after medication, contributing to its market growth.

Competitive Landscape

The market for finasteride is competitive, with several generic versions available. However, the brand name Propecia, owned by Merck & Co., remains a significant player due to its established reputation and efficacy.

Regulatory Environment

Regulatory approvals and guidelines play a crucial role in the market dynamics of finasteride. The FDA has approved Propecia for the treatment of male pattern hair loss, and ongoing clinical trials continue to monitor its safety and efficacy[1][4].

Future Projections and Challenges

Market Expansion

The finasteride market is expected to expand further due to the growing awareness of hair loss treatments and the increasing prevalence of BPH. Emerging markets, particularly in regions with growing middle-class populations, are likely to contribute significantly to this growth.

Challenges and Opportunities

Despite the positive outlook, the market faces challenges such as the potential for side effects, which could impact patient compliance. However, advancements in drug formulation and delivery systems may offer opportunities to mitigate these side effects and enhance patient satisfaction.

Key Takeaways

  • Clinical Efficacy: Propecia has been proven effective in treating male pattern hair loss, with significant hair growth observed in clinical trials.
  • Market Growth: The global finasteride market is projected to grow at a CAGR of around 2.7% from 2025 to 2037.
  • Drivers: Increasing prevalence of hair loss and BPH, rising awareness, and economic factors are driving market growth.
  • Challenges: Potential side effects and regulatory environments are key challenges to be addressed.

FAQs

What is Propecia used for?

Propecia, or finasteride, is used primarily to treat male pattern hair loss and benign prostatic hyperplasia (BPH).

What are the common side effects of Propecia?

Common side effects include decreased libido, erectile dysfunction, and ejaculation disorders, which are generally reversible upon discontinuation of the drug[4].

How effective is Propecia in treating hair loss?

Clinical trials have shown that Propecia significantly increases hair growth, with 77% of men treated with Propecia showing increased hair growth by the fifth year of the study[1].

What is the projected market size of finasteride by 2037?

The finasteride market is expected to reach approximately USD 159.01 million by 2037[5].

Are there any long-term risks associated with Propecia?

Long-term use of finasteride has been associated with a small risk of male breast neoplasia, although the relationship is not fully understood[4].

Sources

  1. PROPECIA® - accessdata.fda.gov
  2. Finasteride Oral Tablet Strategic Insights for 2025 and Forecasts to ... - datainsightsmarket.com
  3. Clinical Trials Market Size, Share & Analysis Report, 2024-2033 - novaoneadvisor.com
  4. PROPECIA (finasteride) tablets - accessdata.fda.gov
  5. Finasteride Market Size & Share, Growth Report 2037 - researchnester.com

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.